Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.620
-0.040 (-6.06%)
At close: Jun 26, 2026, 4:00 PM EDT
0.677
+0.057 (9.26%)
After-hours: Jun 26, 2026, 5:34 PM EDT
Company Description
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
| Phone | 908 967 6677 |
| Website | citiusonc.com |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| CUSIP Number | 17331Y109 |
| ISIN Number | US17331Y1091 |
| Employer ID | 99-4362660 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chief Executive Officer, President and Executive Chairman |
| Myron Z. Holubiak | Secretary and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | EFFECT | Notice of Effectiveness |
| Jun 4, 2026 | SCHEDULE 13D/A | Filing |
| Jun 1, 2026 | 424B3 | Prospectus |
| Jun 1, 2026 | 8-K | Current Report |
| May 29, 2026 | DEF 14C | Filing |
| May 29, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 22, 2026 | 424B3 | Prospectus |
| May 19, 2026 | PRE 14C | Filing |
| May 15, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |